Driving Pre-Clinical Anti-HBV Activity With a Novel Multi-TLR Agonist Therapeutic Vaccine

Time: 12:00 pm
day: Day Two


• Ensuring safe induction of innate and adaptive immune pathways

• Exploring the inhibition of plasma and liver viral DNA loads, as well as HBsAg and HBeAg

• Discussing the potential safe synergy with standard of care